AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KJUN 102 min read$AQST

Aquestive Therapeutics, Inc. (AQST): Submission of Matters to a Vote of Security Holders

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. aqst-20260610 0001398733 false 0001398733 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): J

Original reporting
SEC EDGAR 8-K
Published Jun 10, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$AQST
Neutral
high confidence
Mentioned
$AQST
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AQSTNeutralLow
01

Why it matters

Vote outcomes confirm governance items (Class II director nominees, non-binding advisory executive compensation, and KPMG LLP as independent auditor) but do not introduce new business information.

02

Market read

Primarily a compliance/governance update; limited trading relevance absent additional context (e.g., contested outcomes, strategic changes).

03

What to watch

Traders may still check whether any director election or auditor ratification was contested, but this 8-K provides only vote counts, not reasons or implications.

Relevance 6/10Novelty 2/10Timing: Filed June 10, 2026 (after market)

Background

The SEC 8-K Item 5.07 reports the final voting results from the company’s annual stockholder meeting held June 10, 2026.

Company-level read

Ticker impact

$AQSTNeutralHigh confidence
Context

Aquestive Therapeutics filed an 8-K reporting final results of its June 10, 2026 annual meeting votes, including director elections and auditor ratification.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around governance/auditor matters.

Evidence & confidence

The filing only reports voting tallies for board nominees, advisory executive comp, and KPMG ratification; it does not disclose new guidance, trial/product updates, financing, or enforcement actions.

Market effects

Sector

Minimal; no sector-wide regulatory/clinical/financing signal is introduced.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

If the vote outcomes were materially different from expectations (not provided here), it could briefly affect sentiment, but the filing text lacks any such context.

Key entities

  • issuer
    Aquestive Therapeutics, Inc.

    Company filing the 8-K; reported annual meeting vote results.

  • auditor
    KPMG LLP

    Independent registered public accounting firm ratified for fiscal year ending Dec. 31, 2026.

  • governance
    Board of Directors (Class II nominees)

    Director nominees elected to serve until the 2029 annual meeting.

Read at source← All news

Related articles

OCT 16
$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.

investing.com2 min
OCT 15
$AQSTMed

Aquestive Therapeutics Wins FDA Acceptance Of Anaphylm NDA Resubmission

Aquestive Therapeutics (AQST) announced the FDA accepted its resubmission for Anaphylm, a sublingual epinephrine film for severe allergic reactions. The FDA set a PDUFA goal date of March 16, 2027. The company addressed prior FDA concerns in the resubmission. If approved, Anaphylm could offer a needle-free treatment option. AQST stock closed at $4.61, up 1.30% in pre-market trading.

rttnews.com3 min
OCT 15
$AQSTMedAI 8/10

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Regulation FD Disclosure. Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 • FDA accepted the resubmission as complete and classified it as a Class 2 response • Prescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027

SEC EDGAR 8-K2 min
OCT 14
$ETONMed

Eton Licenses LIBERVANT For U.S. Seizure Rescue Market

Eton Pharmaceuticals (ETON) and Aquestive Therapeutics (AQST) signed an exclusive U.S. licensing agreement for LIBERVANT, a buccal film seizure rescue therapy. Eton gains commercialization rights, while Aquestive will manufacture. The U.S. seizure rescue market is estimated at over $450 million annually. LIBERVANT is expected to launch in April 2027, pending FDA approval. Both companies' stocks showed mixed trading activity.

rttnews.com2 min